Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211657 | 0.88 | POLB (0.42) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5215135 | 0.83 | POLB (0.44) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5212655 | 0.82 | RXRA (0.47) | MAPTHPGDHTT | |
| SCHEMBL5208646 | 0.80 | POLB (0.45) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5212167 | 0.79 | POLB (0.38) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5209112 | 0.77 | POLB (0.40) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5206601 | 0.77 | POLB (0.39) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5213964 | 0.76 | KMT2A (0.44) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5208350 | 0.75 | MAPT (0.40) | NPC1RAB9APOLBMAPTTACR1 | |
| SCHEMBL5212083 | 0.74 | QPCT (0.44) | MEN1KMT2APOLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | MEN1 1626/4885KMT2A 680/4885NPC1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.